ReNeuron cleared to proceed with groundbreaking stem cell study

An independent monitoring board has given ReNeuron a green light to continue with a pioneering study in which stem cells are being injected into the brains of stroke victims. After reviewing the responses of the first three patients, the biotech will now try a higher dose. "Data from the laboratory safety tests, neurological examinations and neurofunctional tests conducted thus far indicate that the ReN001 treatment is safe and well-tolerated at the initial dose," said the U.K. company. Story

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.